Table 1 Suggested medicines to be included in the WHO EML
From: Revising the WHO Essential Medicines List for paediatric rheumatology
Drug | Should Include (Ideal) (% refers to respondents) | Inclusion ‘Essential’ |
|---|---|---|
Oral prednisolone | 100% | 92% |
Oral NSAIDs | 99% | 93% |
Hydroxychloroquine | 98% | 88% |
Intravenous Methylprednisolone | 98% | 83% |
Methotrexate oral | 96% | 81% |
Mycophenolate Mofetil | 95% | 77% |
Azathioprine | 94% | 71% |
Methotrexate subcutaneous | 91% | 80% |
Intravenous cyclophosphamide | 91% | 77% |
Adalimumab | 91% | 71% |
Anakinra | 90% | 60% |
Etanercept | 87% | 70% |
Intra-articular corticosteroid Triamcinolone Hexacetonide | 86% | 64% |
Intravenous Tocilizumab | 86% | 63% |
Oral prednisolone (soluble) | 86% | 55% |
Ciclosporin | 85% | 52% |
Sulphasalazine | 84% | 51% |
Subcutaneous Tocilizumab | 81% | 46% |
Infliximab | 80% | 52% |
Intravenous bisphosphonate (e.g. pamidronate) | 76% | 37% |
Intra-articular corticosteroid Triamcinolone Acetonide | 72% | 28% |
Intra-articular corticosteroid Methylprednisolone | 45% | 25% |
Oral cyclophosphamide | 41% | 16% |
Inhaled analgesia (nitrous oxide) | 36% | 15% |
Thalidomide | 34% | 8% |
Total Respondents: 97 |